GLP-1 receptor agonists and dual incretin agonists
GLP-1 receptor agonists and dual incretin agonists has been studied in 2 papers since 2026: none in people yet, 2 reviews; 2 in the past year. No study of it in people or animals has been published yet. The newest paper, Oct 5, 2026: “Glucagon-like peptide-1 receptor agonists and aesthetic surgery: perioperative safety, timing, durability and body composition”.
2 papers study it3 findingsUpdated
2 new papers in 30 daysSee all 2
What did studies of GLP-1 receptor agonists and dual incretin agonists find?
2Studies of GLP-1 receptor agonists and dual incretin agonists measured 2 outcomes; the most studied are body weight (2 studies) and obstructive sleep apnea severity (1).
Body weight
downin humans2
2 studies
Body weight
downin humans2
GLP-1 receptor agonists and dual incretin agonists decrease body weight in humans (double-digit percentage weight loss).
“By producing double-digit percentage weight loss, these agents expand eligibility for elective procedures”
Review
Frontiers in endocrinology
GLP-1 receptor agonists and dual incretin agonists decrease body weight in humans.
“glucagon-like peptide-1 receptor agonists and dual incretin agonists have demonstrated clinically relevant reductions in body weight and OSA severity”
Reviewobstructive sleep apnea
Clocks & sleep
Obstructive sleep apnea severity
downin humans1
1 study
Obstructive sleep apnea severity
downin humans1
GLP-1 receptor agonists and dual incretin agonists decrease obstructive sleep apnea severity in humans.
“glucagon-like peptide-1 receptor agonists and dual incretin agonists have demonstrated clinically relevant reductions in body weight and OSA severity”
Reviewobstructive sleep apnea
Clocks & sleep